Panobinostat
Panobinostat
Definition
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.
Also known as (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, Faridak, LBH 589, LBH-589, LBH589, PANOBINOSTAT — per NCIT
Also identified as
- ATC L01XH03 per RXNORM
- NCIT NCIT:C66948 per NCIT
- SCTID 429068009 per RXNORM
- SCTID 429398005 per RXNORM
- UNII 9647FM7Y3Z per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Multiple myeloma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.